Detalhes bibliográficos
| Autor(a) principal: |
Gilbert,Benjamin |
| Data de Publicação: |
1992 |
| Tipo de documento: |
Artigo
|
| Idioma: |
eng |
| Título da fonte: |
Memórias do Instituto Oswaldo Cruz |
| Texto Completo: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700060
|
Resumo: |
The appears to be no chemical manufacture of antimalarial drugs is Brazil. Technology at laboratory process level has been developed for chloroquine, mefloquine, pyrimethamine and cycloquanil, but not perfected nor scaled-up, largely for economic reasons and market uncertainty. Development of primaquine has been contracted but it will run into the same difficulty. Manufacturing capacity for sulfadoxine was registred in the SDI by Roche. A project to produce artemisinine and its derivates is under way at UNICAMP-CPQBA but is hampered by low content in the plant. Proguanil could be produced easily, but apparently no attempt has been made to do so. Quinine is imported on a large scale mostly for softdrink production. Since malarial treatment falls largely within responsability of the Government health authorities, manufacture of drugs in Brazil will depend on an assured medium-term purchase order made to a potential local manufacturer, since competition in the world market is scarcelyviable at the present moment. |